- Abaloparatide
-
- $1.00 / 1kg
-
2025-12-29
- CAS:247062-33-5
- Min. Order: 0.10000000kg
- Purity: 99%
- Supply Ability: 200kg
- Abaloparatide
-
- $0.00 / 1g
-
2025-12-29
- CAS:247062-33-5
- Min. Order: 1g
- Purity: 98%min
- Supply Ability: 500KG
- Abaloparatide Acetate
-
- $1000.00 / 1g
-
2025-12-15
- CAS:247062-33-5
- Min. Order: 1g
- Purity: >=99% (HPLC), USP43
- Supply Ability: 10000000g
|
| | Abaloparatide Basic information |
| | Abaloparatide Chemical Properties |
| form | Solid | | color | White to off-white | | Sequence | H-Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-N-Me-Ala-Lys-Leu-His-Thr-Ala-NH2 | | InChIKey | BVISQZFBLRSESR-XSCWXTNMSA-N |
| | Abaloparatide Usage And Synthesis |
| Description | Abaloparatide is a parathyroid hormone receptor 1 (PTHR1) analog and a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide is used to treat osteoporosis. | | Uses | Abaloparatide, a synthetic peptide analog of parathyroid hormone-related protein (PTHrP), has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of osteoporosis in specific patient populations. The drug is indicated for postmenopausal women who are at a high risk of fracture, which can be defined by a history of osteoporotic fracture, multiple risk factors for fracture, or those who have failed or are intolerant to other available osteoporosis therapies.
In addition to its use in postmenopausal women, abaloparatide has also been approved for increasing bone density in men with osteoporosis who are at high risk for fractures. This approval extends to adult patients who have not responded effectively to or cannot tolerate other osteoporosis treatments. The drug is designed to stimulate bone formation, thereby reducing the risk of fractures associated with osteoporosis. | | Brand name |
Tymlos
| | Mechanism of action | Abaloparatide is a human parathyroid hormone-related peptide [PTHrP(1-34)] analog, which acts as an agonist at the PTH1 receptor (PTH1R). This results in activation of the cAMP signaling pathway in target cells. In rats and monkeys, abaloparatide had an anabolic effect on bone, demonstrated by increases in BMD and bone mineral content (BMC) that correlated with increases in bone strength at vertebral and/or nonvertebral site. | | Side effects | Abaloparatide is well tolerated and has mild adverse effects. Patients may experience nausea, dizziness, headache, palpitations, and hypercalciuria. Abaloparatide has been associated with supraventricular extrasystoles and orthostatic hypotension. The common (≥5%) treatment-emergent adverse drug reactions in men with osteoporosis are injection site reactions, nasopharyngitis, arthralgia, bronchitis, and hypertension.
The adverse effects reported from a randomized, double-blind, placebo-controlled trial among postmenopausal women with osteoporosis receiving 80 mcg of abaloparatide daily for 18 months include hypercalcemia (11%), dizziness (10%), nausea (8%), headache (8%), palpitations (5%), fatigue (3%), upper abdominal pain (3%), and vertigo (2%). | | in vivo | Abaloparatide (20-80 μg/kg; s.c.; daily for 30 days) enhances bone formation and cortical structure in mouse[1]. | Animal Model: | 16-week-old wild-type (WT) female C57BL/6J mice[1] | | Dosage: | 20-80 μg/kg | | Administration: | S.c.; daily for 30 days | | Result: | Efficiently expanded cortical thickness (Ct. Th) at both doses of 20 and 80 μg/kg/day by 17% and 18%, respectively, increased P1NP levels to 227% and 407% at 20 and 80 μg/kg/day, respectively. |
| Animal Model: | Female Sprague-Dawley rats (age 22 weeks)[2] | | Dosage: | 1 μg/kg, 5 μg/kg, 25 μg/kg | | Administration: | Subcutaneous injection; daily; for 12 months | | Result: | Increased biochemical bone formation markers, histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces. Induced substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture. Stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density. Whole-body bone mineral density (BMD) was increasing 25%. |
|
| | Abaloparatide Preparation Products And Raw materials |
|